Clinical Trials Logo

Lymphoma clinical trials

View clinical trials related to Lymphoma.

Filter by:
  • Approved for marketing  
  • Page 1

NCT ID: NCT05733650 Approved for marketing - Clinical trials for Large B-cell Lymphoma

Expanded Access Program for Epcoritamab

Start date: n/a
Phase:
Study type: Expanded Access

The purpose of this program is to provide investigational epcoritamab, an antibody also known as GEN3013 (DuoBody-CD3xCD20), in an expanded access setting for eligible patients with relapsed and/or refractory (R/R) large B-cell lymphoma (LBCL) who have a high unmet medical need with no other treatment options. It is a requirement that patients do not qualify for an ongoing epcoritamab clinical program or are unable to participate due to logistical reasons. Access to investigational epcoritamab can be requested by contacting preapprovalaccessprograms@genmab.com.

NCT ID: NCT04943952 Approved for marketing - Clinical trials for Acute Lymphoblastic Leukemia

JZP458 - Recombinant Erwinia Asparaginase for Treatment of ALL / LBL Patients With Hypersensitivity to E. Coli-derived Asparaginase

Start date: n/a
Phase:
Study type: Expanded Access

This study is an Expanded Access Protocol (EAP) of JZP458 in participants with ALL/LBL who are hypersensitive to an E.coli-derived asparaginase (allergic reaction or silent inactivation) and unable to access alternative licensed treatment, to receive JZP458 treatment prior to potential Food and Drug Administration (FDA) approval and commercial availability.

NCT ID: NCT03153462 Approved for marketing - Clinical trials for Relapsed/Refractory Diffuse Large B Cell Lymphoma

Axicabtagene Ciloleucel Expanded Access Study

ZUMA-9
Start date: n/a
Phase:
Study type: Expanded Access

A multicenter, open-label expanded access protocol for the treatment of subjects with relapsed/refractory large B-cell lymphoma. Subjects who received an infusion of axicabtagene ciloleucel will complete the remainder of the 15 year follow-up assessments in a separate long-term follow-up study, KT-US-982-5968

NCT ID: NCT01833039 Approved for marketing - Clinical trials for Relapsed or Refractory Mantle Cell Lymphoma

An Open Label Treatment Use Protocol for Ibrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma

Start date: n/a
Phase:
Study type: Expanded Access

The purpose of this study is to provide patients who have relapsed or refractory Mantle Cell Lymphoma (MCL) with early access to an investigational medication called ibrutinib (PCI-32765) and to collect safety information about the drug.